EPHB4 and rhabdomyosarcoma: EPHB4, specifically, has been highlighted as a potential therapeutic target for alveolar rhabdomyosarcoma, with studies suggesting its role as a poor prognostic indicator in certain cell lines (especially A203, RD-ES, and A673) [122,123,124].